Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

unknown1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (50.0%)
Phase 31 (50.0%)

Trials by Status

unknown133%
terminated133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
withdrawnphase_2

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

NCT04910425
terminatedphase_3

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

NCT04457245
unknown

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

NCT03501940

Clinical Trials (3)

Showing 3 of 3 trials
NCT04910425Phase 2

PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer

Withdrawn
NCT04457245Phase 3

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Terminated
NCT03501940

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3